E Woldemussie
Overview
Explore the profile of E Woldemussie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
435
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiquet C, Drouyer E, Woldemussie E, Ruiz G, Wheeler L, Denis P, et al.
J Fr Ophtalmol
. 2006 Sep;
29(7):847-51.
PMID: 16988637
Glaucoma is a chronic optic neuropathy leading to a degeneration of retinal ganglion cells. There is accumulating evidence that glaucomatous damage extends from retinal ganglion cells to vision centers in...
2.
Woldemussie E, Ruiz G, Wijono M, Wheeler L
Invest Ophthalmol Vis Sci
. 2001 Nov;
42(12):2849-55.
PMID: 11687528
Purpose: To examine the neuroprotective effect of the alpha(2)-adrenergic agonist brimonidine in a chronic ocular hypertension model. Methods: Intraocular pressure (IOP) was elevated by laser photocoagulation of episcleral and limbal...
3.
Wheeler L, Woldemussie E
Eur J Ophthalmol
. 2001 Oct;
11 Suppl 2:S30-5.
PMID: 11592528
Purpose: The glaucomas are characterized by chronic progressive ganglion cell loss over many years. A drug with neuroprotective activity should increase the resistance of retinal ganglion cells (RGC) to chronic...
4.
Gil D, Spalding T, Kharlamb A, Skjaerbaek N, Uldam A, Trotter C, et al.
Life Sci
. 2001 Jun;
68(22-23):2601-4.
PMID: 11392632
Pilocarpine has been used to lower intraocular pressure (IOP) in glaucoma patients for more than 100 years. Since the identification of five muscarinic receptor subtypes, there has been an interest...
5.
Wheeler L, Gil D, Woldemussie E
Surv Ophthalmol
. 2001 May;
45 Suppl 3:S290-4; discussion S295-6.
PMID: 11377451
The loss of retinal ganglion cells (RGCs) in glaucoma occurs progressively over many years. A neuroprotective drug should enhance survival of RGCs in the presence of chronic stress/injury. Four criteria...
6.
Hare W, Woldemussie E, Lai R, Ton H, Ruiz G, Feldmann B, et al.
Surv Ophthalmol
. 2001 May;
45 Suppl 3:S284-9; discussion S295-6.
PMID: 11377450
Glutamatergic excitotoxicity has been implicated as a mechanism for injury in a variety of central nervous system pathologies, including glaucoma. Memantine, an NMDA-type glutamatergic open-channel blocker, has pharmacologic properties that...
7.
Schori H, Kipnis J, Yoles E, Woldemussie E, Ruiz G, Wheeler L, et al.
Proc Natl Acad Sci U S A
. 2001 Mar;
98(6):3398-403.
PMID: 11248090
Our group recently demonstrated that autoimmune T cells directed against central nervous system-associated myelin antigens protect neurons from secondary degeneration. We further showed that the synthetic peptide copolymer 1 (Cop-1),...
8.
Hare W, Ton H, Ruiz G, Feldmann B, Wijono M, Woldemussie E
Invest Ophthalmol Vis Sci
. 2001 Jan;
42(1):127-36.
PMID: 11133857
Purpose: To characterize, using both conventional and multifocal electroretinogram (ERG) recordings as well as histologic measures, retinal injury in the chronic ocular hypertensive primate model for experimental glaucoma. Methods: Ocular...
9.
Hare W, Ton H, Woldemussie E, Ruiz G, Feldmann B, Wijono M
Eur J Ophthalmol
. 1999 May;
9 Suppl 1:S30-3.
PMID: 10230603
Purpose: This study was performed to determine whether components of the standard ERG (electroretinogram), multifocal ERG, and flash VECP (visually-evoked cortical potential) response might provide a sensitive measure of retinal...
10.
Wheeler L, Lai R, Woldemussie E
Eur J Ophthalmol
. 1999 May;
9 Suppl 1:S17-21.
PMID: 10230601
Purpose: The selective alpha-2 agonist brimonidine was used as a pharmacological probe to activate alpha 2 receptor-mediated neuroprotective signaling pathways and quantitate the enhancement of retinal ganglion cell survival and...